FDA's AI Drug Watch: Comment on Safety Tech Revolution
Published Date: 2/18/2026
Notice
Summary
The FDA is asking for public feedback on a new plan to use smart technology like AI to better track drug safety after medicines hit the market. This affects drug companies who must report safety info and could speed up how quickly problems are spotted. Comments are open until March 20, 2026, so now’s the time to weigh in on this tech upgrade that aims to keep medicines safer and reporting smoother.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Industry Meeting Burden: 10–30 Hours
If your organization wants to present to FDA under the Emerging Drug Safety Technology Program, you must prepare an initial meeting proposal (about 10 hours). If selected, you must prepare and deliver a 20–50 minute presentation, which FDA estimates will take about 30 hours. FDA estimates 25 organizations will request presentations per year, about 12 meetings will be held per year, and the total annual burden across respondents is 610 hours.
Faster Drug Safety Detection
The FDA says using AI and other emerging technologies in postmarket pharmacovigilance could create more efficiencies and help spot safety problems sooner. The Emerging Drug Safety Technology Program is meant to accelerate FDA's understanding of these tools so problems with medicines may be identified more quickly.
May Shape Future AI Drug Rules
FDA will use information from Emerging Drug Safety Technology meetings to inform potential regulatory and policy approaches for AI and other emerging technologies in postmarket safety surveillance. If your organization develops or uses AI for pharmacovigilance, what you share could influence future FDA policies.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-03091, Agency Information Collection Activities; Proposed eCollection eComments Requested; Title-National Incident-Based Reporting System (NIBRS)
The FBI wants to keep collecting crime data through the National Incident-Based Reporting System (NIBRS) and is asking for your feedback on how to make it easier and better. This affects law enforcement agencies who report crime info and could save them time with improved electronic forms. You’ve got until March 20, 2026, to share your thoughts before the government decides on the final plan.
Next: 2026-03094, Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA wants your thoughts on how they collect info about patent term restoration and due diligence petitions. This affects companies dealing with drug patents who file petitions to extend patent life. Comments are open until April 20, 2026, so get ready to share your views—no fees, just your input!